SynthesisFrontiers in pharmacology2026
Efficacy and safety of yaobitong capsules for lumbar disc herniation: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lumbar disc herniation (LDH) is a major contributor to the global burden of low back pain. Yaobitong (YBT) capsules are a commercial Chinese polyherbal preparation that has been widely used to treat LDH. However, its efficacy and safety require comprehensive evaluation. Methods: A comprehensive search was conducted across eight databases, retrieving literature from the inception of each database up to 31 October 2025. Randomized controlled trials (RCTs) evaluating YBT alone or in combination with standard pharmacological therapy were included. Subgroup and sensitivity analyses explored outcome stability. Publication bias was assessed using funnel plots, Egger's test, and Begg's rank correlation test. Study quality was evaluated using the Cochrane Risk of Bias (RoB) tool, and evidence certainty was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Meta-analysis was performed using RevMan 5.3 and R software. Results: Seventeen RCTs involving 1,752 patients with LDH were included. Compared with standard pharmacological therapy, YBT capsules significantly improved VAS (MD = -1.37, 95% CI: -1.60 to -1.14), ODI (MD = -5.36, 95% CI: -6.56 to -4.16), and JOA scores (MD = 5.21, 95% CI: 3.66-6.75). Additionally, YBT capsules significantly reduced levels of inflammatory cytokines including IL-6, IL-8, and TNF-α, supporting potential anti-inflammatory effects. Adverse events were mild and less frequent in the YBT capsules group (RR = 0.34, 95% CI: 0.18-0.67). Subgroup and sensitivity analyses demonstrated consistent results across varying sample sizes, treatment periods, and regimens, supporting the robustness of the study findings. Conclusion: YBT capsule-based therapy was associated with reduced pain, improved functional outcomes, and suppressed inflammatory responses in LDH, while exhibiting a favorable short-term safety profile. These findings support YBT capsules as a potentially effective adjunct to conventional therapy. However, most trials were small, single-center studies conducted in China. Large-scale, multicenter RCTs with standardized outcomes are needed to confirm long-term safety and clinical utility. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251232067, identifier CRD420251232067.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.